(+)-Shikonin

SKU: orb1309685

Description

Shikonin

Research Area

Cell Biology, Immunology & Inflammation, Infectious Disease & Virology, Metabolism Research, Pharmacology & Drug Discovery, Protein Biochemistry, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	517-89-5
MW	288.30
Purity	99.11%
Formula	C₁₆H₁₆O₅
SMILES	CC(C)=CC[C@@H](O)C1=CC(=O)c2c(O)ccc(O)c2C1=O
Target	Chloride channel,TNF,HIV Protease,PKM,NF-κB,AIM2
Solubility	Ethanol:13.00 mg/mL (45.09 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5.70 mg/mL (19.77 mM);DMSO:130.00 mg/mL (450.92 mM);H2O:Insoluble

Bioactivity

−

Target IC50	TMEM16A (Cl- channel):6.5 μM\|PKM2 (FBP presence):0.8 μM\|PKM2 (FBP absence):0.3 μM
In Vivo	METHODS: To investigate the efficacy against murine colitis, (+)-Shikonin (6.125-25 mg/kg) was administered by gavage to a DSS-induced Balb/c mouse model of colitis once daily for seven days. RESULTS: (+)-Shikonin attenuated the overall symptoms of DSS-induced colitis in mice and reduced colonic injury. METHODS: To detect anti-tumor activity in vivo, (+)-Shikonin (0.1-10 mg/kg) was administered intraperitoneally to SCID mice bearing human melanoma B16 once daily for nine days. RESULTS: (+)-Shikonin treatment inhibited B16 cell growth in SCID mice in a dose-dependent manner. Read more...
In Vitro	METHODS: Human glioma cells U87 and U251 were treated with (+)-Shikonin (2.5-7.5 μmol/L) for 12-72 h. Cell viability was measured by CCK-8. RESULTS: (+)-Shikonin inhibited the proliferation of U87 and U251 cells in a time- and dose-dependent manner. METHODS: Macrophages RAW264.7 were pretreated with (+)-Shikonin (0.5-2 μM) for 1 h, then treated with LPS (250 ng/mL) and IFN-γ (100 ng/mL) for 24 h. Inflammatory factor levels were measured using RT-qPCR and ELISA. RESULTS: In LPS+IFN-γ-mimicked RAW264.7 cells, mRNA and protein expression of IL-1β, IL-6 and TNF-α were reduced. Read more...
Cell Research	U87 and U251 cells are seeded into 96-well plates at a density of 1×104 cells per well in standard DMEM and incubated for 24 h under standard conditions (37°C and 5% CO2). Then the medium is replaced with either blank, serum-free DMEM or DMEM containing (+)-Shikonin at concentrations of 2.5, 5, and 7.5 μM. The total volume in each well is 200 μL. Finally, the plates are shaken softly and the optical density is recorded at 570 nm (OD570) using a plate reader. At least three independent experiments are performed. Read more...
Animal Research	Healthy male Sprague-Dawley rats (n=30; 8 to 10-weeks old, 250 to 300 g) are used in this study. Rats were randomly assigned to three groups: Sham-operated group (n=10), osteoarthritis model group (n=10) and (+)-Shikonin-treated group (n=10). In the sham-operated group, the right knee joint of the anesthetized rat is only exposed under sterile conditions, and the rats are treated with 0.1 ml/100 g physiological saline (i.p.). In the osteoarthritis model group, osteoarthritis model rats were treated with 0.1 ml/100 g physiological saline (i.p.). In the (+)-Shikonin-treated group, osteoarthritis model rats are treated with 10 mg/kg (+)-Shikonin(i.p.) once daily for 4 days after osteoarthritis modeling. Read more...

Storage & Handling

−

Storage	keep away from direct sunlight,store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Chloride channel, Chloride Channel, Chloridechannel, Cl? Channels, Alkanna Red, (+)-Shikonin, (R)-(+)-Shikonin, C.I. 75535, Anchusa acid, NSC252844, NSC-252844, NSC 252844, Inhibitor, Isoarnebin 4, Isoarnebin4, Isoarnebin-4, inhibit, NF-kB, NFkB, Pyruvate Kinase, NF-κB, NFκB, Nuclear factor-kappaB, Nuclear factor-κB, Human immunodeficiency virus, HIV, HIV Protease, HIVProtease, Shikonin, TNF-α, TNFR, PKM2, TMEM16A chloride channel, TNF Receptor, Tumor Necrosis Factor Receptor

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

479503 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

(+)-Shikonin (orb1309685)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Purity:	98.0%（HPLC e.e.40%）
CAS Number:	517-89-5

MW:	697.92
Formula:	C₃₆H₄₃NO₇S₃

CAS Number:	104056-81-7
MW:	258.312
Formula:	C₁₆H₁₈O₃

CAS Number:	52387-15-2
MW:	372.41
Formula:	C₂₁H₂₄O₆

Purity:	99.73%
CAS Number:	54952-43-1
MW:	288.3
Formula:	C₁₆H₁₆O₅

(+)-Shikonin

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Shikonin [orb702125]

PKM2/PDK1-IN-1 [orb1982596]

Deoxyshikonofuran [orb2942975]

(2-Methylbutyryl)shikonin [orb1684063]

(±)-Shikonin [orb1304876]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

(+)-Shikonin (orb1309685)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors